公开(公告)号：US11839607B2

公开(公告)日：2023-12-12

申请号：US16978202

申请日：2019-02-22

Applicant: HEFEI KEDA BIO-TECHNOLOGY CO. LTD

Inventor： Ke Wang ,  Qianliu Cheng ,  Zonggui Wang ,  Yan Geng ,  Xun Zhao

IPC: A61K31/4525 ,  A61K31/13 ,  A61K31/265 ,  A61K31/445 ,  A61K31/55 ,  C07C211/38 ,  C07D405/12

CPC classification number: A61K31/4525 ,  A61K31/13 ,  A61K31/265 ,  A61K31/445 ,  A61K31/55 ,  C07C211/38 ,  C07D405/12 ,  C07B2200/13

Abstract: A memantine paroxetine cocrystal salt and its preparation method, pharmaceutical composition and application thereof are provided. The cocrystal salt of the invention is memantine paroxetine sulfate hydrate. Its mechanism of action is 5-HT inhibitor and NMDA receptor antagonist. It is a multi-target drug. The preliminary pharmacokinetic experiments showed that the main pharmacokinetic parameters of cocrystal salt and memantine, such as T1/2, Tmax, Cmax and AUC(0-∞), were significantly different. The results also showed that cocrystal salt could improve drug absorption, blood drug concentration, bioavailability and curative effect. This provides a material basis for reducing dosage and adverse drug reactions. In addition to that the cocrystal salt of this invention can be used as a multi-target drug, it can also combine with other drugs of different action mechanisms to form compound preparations or be used in combination, so as to obtain unexpected clinical efficacy.

公开(公告)号：US11834663B2

公开(公告)日：2023-12-05

申请号：US17365260

申请日：2021-07-01

Applicant: Monash University

Inventor： Siew Yeen Chai ,  Robert Widdop ,  Tracey Gaspari ,  Huey Wen Lee

IPC: A61K31/395 ,  A61K31/351 ,  A61K31/4433 ,  A61P11/16 ,  A61P9/00 ,  A61P13/12 ,  C12N15/113 ,  A61K31/4709 ,  A61K31/55 ,  A61P1/16

CPC classification number: C12N15/1137 ,  A61K31/351 ,  A61K31/395 ,  A61K31/4433 ,  A61K31/4709 ,  A61K31/55 ,  A61P1/16 ,  A61P9/00 ,  A61P13/12 ,  C12N2310/14

Abstract: The present invention relates to compositions, methods and kits for the treatment of fibrosis. In particular, the compositions, methods and kits are particularly useful, but not limited to, the treatment of cardiac fibrosis. The invention provides a method of treating fibrosis in an individual comprising administering an inhibitor of insulin-regulated aminopeptidase (IRAP), thereby treating fibrosis.

公开(公告)号：US20230381194A1

公开(公告)日：2023-11-30

申请号：US18363848

申请日：2023-08-02

Applicant: OTSUKA PHARMACEUTICAL CO., LTD.

Inventor： Akitsuna AKAGI ,  Kai SUZUKI ,  Atsuya NAKAMURA ,  Toru NISHIBAYASHI

IPC: A61K31/55 ,  A61K9/16 ,  A61K9/00 ,  A61K9/10 ,  A61K47/38 ,  A61K47/26

CPC classification number: A61K31/55 ,  A61K9/1652 ,  A61K9/0095 ,  A61K9/0053 ,  A61K9/10 ,  A61K47/38 ,  A61K47/26

Abstract: This invention provides a suspension for oral administration comprising particles containing amorphous tolvaptan that can inhibit or delay crystallization of amorphous tolvaptan over time in the suspension, and stably maintain high solubility of tolvaptan and excellent absorbability of tolvaptan from the gastrointestinal tract; and a solid formulation for oral administration that can be suspended to prepare the suspension for oral administration at the time of use. This invention relates to a suspension for oral administration, in particular, a syrup, comprising (a) particles containing amorphous tolvaptan, (b) hydroxypropyl methylcellulose (HPMC), and (c) a solvent, wherein the amount of the HPMC (b) is 0.1 to 25% by weight based on the total weight of the suspension for oral administration.

公开(公告)号：US11826430B2

公开(公告)日：2023-11-28

申请号：US15931495

申请日：2020-05-13

Applicant: Nuvation Bio Inc.

Inventor： David Hung ,  Son Minh Pham ,  Sarvajit Chakravarty ,  Jiyun Chen ,  Jayakanth Kankanala ,  Jeremy D. Pettigrew ,  Anup Barde ,  Anjan Kumar Nayak

IPC: C07D471/04 ,  C07D471/06 ,  C07D401/12 ,  A61K47/55 ,  A61K31/4745 ,  C07D401/14 ,  C07D403/12 ,  A61K9/00 ,  A61K47/68 ,  A61K31/502 ,  A61K31/55 ,  A61K31/5377 ,  A61K31/498 ,  A61K31/52 ,  A61K31/5025 ,  A61K31/438 ,  A61K31/519 ,  A61K31/4985

CPC classification number: A61K47/55 ,  A61K9/0053 ,  A61K31/438 ,  A61K31/4745 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/519 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/55 ,  A61K47/6877 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D471/04 ,  C07D471/06

Abstract: The disclosure relates to anti-cancer compounds derived from nuclear steroid receptor binders, to products containing the same, as well as to methods of their use and preparation.

公开(公告)号：US20230364039A1

公开(公告)日：2023-11-16

申请号：US18030491

申请日：2021-10-14

Applicant: Emory University

Inventor： Jeff Sands ,  Janet Klein

IPC: A61K31/16 ,  A61K31/55 ,  A61P13/00

CPC classification number: A61K31/16 ,  A61K31/55 ,  A61P13/00

Abstract: This disclosure relates to methods of managing polyuria as a side effect of vasopressin receptor antagonist therapies. In certain embodiments, this disclosure relates to methods of treating or preventing polyuria as a side effect of a vasopressin receptor antagonist therapy comprising administering a vasopressin receptor antagonist to a human subject in combination with an effective amount of an activator of adenosine monophosphate activated protein kinase (AMPK). In certain embodiments, the subject is diagnosed with autosomal dominant polycystic kidney disease (ADPKD). In certain embodiments, the subject is diagnosed with polyuria.

公开(公告)号：US20230357170A1

公开(公告)日：2023-11-09

申请号：US18316183

申请日：2023-05-11

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： Alan S. VERKMAN ,  Marc H. LEVIN ,  Onur CIL ,  Sujin LEE

IPC: C07D251/46 ,  A61P27/04 ,  C07D413/12 ,  A61K31/496 ,  C07D403/04 ,  A61K31/53 ,  A61K31/5377 ,  A61K45/06 ,  C07D251/52 ,  A61P1/10 ,  A61K31/55

CPC classification number: C07D251/52 ,  A61K31/496 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/55 ,  A61K45/06 ,  A61P1/10 ,  A61P27/04 ,  C07D251/46 ,  C07D403/04 ,  C07D413/12

Abstract: Provided herein are compounds that activate CFTR and methods for treating constipation, dry eye disorders, and other diseases and disorders.

公开(公告)号：US20230348988A1

公开(公告)日：2023-11-02

申请号：US18009885

申请日：2021-06-11

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  FUNDACIO INSTITUT DINVESTIGACIO BIOMEDICA DE BELLVITGE ,  INSTITUT CATALA DONCOLOGIA

Inventor： Mary Helen Barcellos-Hoff ,  Qi Liu ,  Miquel Angel Pujana

IPC: C12Q1/6886 ,  A61K31/282 ,  A61K31/55 ,  A61K45/06 ,  A61P35/00 ,  A61K51/10

CPC classification number: C12Q1/6886 ,  A61K31/282 ,  A61K31/55 ,  A61K45/06 ,  A61P35/00 ,  A61K51/1045 ,  C12Q2600/158

Abstract: Presented are methods of assessing a deficit in DNA damage repair capability in cancer cells. Cancer cells having this DNA damage repair phenotype have increased susceptibility to certain treatments, including genotoxic treatments, treatment with PARP1 inhibitors, and immunotherapies. The methods encompass the use of novel gene expression signatures that enable facile and rapid determination of the DNA damage repair phenotype in cancer cells of a sample. By these methods, subjects having cancer that is amenable to genotoxic treatment, PARP1 inhibition, or immunotherapy may be identified and administered a suitable treatment. Also disclosed is a method of inducing the DNA damage repair deficit phenotype in cancer cells to sensitize them to various treatments.

公开(公告)号：US20230330223A1

公开(公告)日：2023-10-19

申请号：US17921543

申请日：2021-04-26

Applicant: Agendia N.V.

Inventor： Annuska Maria GLAS

IPC: A61K39/395 ,  C12Q1/6886 ,  C12Q1/6874 ,  A61K31/337 ,  A61K31/502 ,  A61K31/55 ,  A61K31/454 ,  A61K31/5025 ,  A61K31/5517 ,  A61P35/00

CPC classification number: A61K39/3955 ,  C12Q1/6886 ,  C12Q1/6874 ,  A61K31/337 ,  A61K31/502 ,  A61K31/55 ,  A61K31/454 ,  A61K31/5025 ,  A61K31/5517 ,  A61P35/00 ,  C12Q2600/158 ,  C12Q2600/118 ,  C12Q1/6841

Abstract: The invention relates to a PARP inhibitor, an immune checkpoint inhibitor, or a combination thereof, for use as a medicament. The invention further relates to a kit of parts and to a pharmaceutical composition comprising a PARP inhibitor and an immune checkpoint inhibitor, preferably for use in a method of treating a breast cancer.

公开(公告)号：US11771678B2

公开(公告)日：2023-10-03

申请号：US17198904

申请日：2021-03-11

Applicant: NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY

Inventor： Shiro Matsumoto ,  Takumi Era ,  Fumio Endo

IPC: A61K31/352 ,  A61K31/137 ,  A61K31/196 ,  A61K31/455 ,  A61K31/52 ,  A61K31/55 ,  A61K31/7076

CPC classification number: A61K31/352 ,  A61K31/137 ,  A61K31/196 ,  A61K31/455 ,  A61K31/52 ,  A61K31/55 ,  A61K31/7076

Abstract: [Object] To clarify the mechanism associated with neuropathy in methylmalonic acidemia and to develop a new therapeutic drug or the like for neuropathy in organic acidemia on the basis of this finding.
[Solving Means] The inventors established technologies for the establishment of iPS cells derived from a methylmalonic acidemia patient and establishment of a stable maintenance and culturing method using peripheral blood lymphocytes of a methylmalonic acidemia patient, and for the differentiation of methylmalonic acidemia patient-derived iPS cells into nerve cells. The inventors made clear that neuropathy in organic acidemia can be treated and prevented by replenishing cAMP using a series of these experiment technologies. The drug of the invention treats or prevents neuropathy by increasing cAMP in organic acidemia.

公开(公告)号：US20230301993A1

公开(公告)日：2023-09-28

申请号：US18019655

申请日：2021-07-23

Applicant: Vyluma Inc.

Inventor： Jack Martin Lipman ,  Kumaresh Soppimath ,  Tushar Hingorani

IPC: A61K31/498 ,  A61K31/27 ,  A61K31/55 ,  A61K31/221 ,  A61K9/00 ,  A61P27/02

CPC classification number: A61K31/498 ,  A61K31/27 ,  A61K31/55 ,  A61K31/221 ,  A61K9/0048 ,  A61P27/02

Abstract: Ophthalmic formulations for treatment of night vision disturbance syndrome (NVD) are presented and preferably comprise brimonidine, rivastigmine, and/or galantamine at very low concentrations. Such formulations unexpectedly provided acute and transient therapeutic effect to alleviate one or more symptoms associated with NVD.